( this threshold for atleast 20 hours p...)Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association,Health

"We are pleased to report strong evidence supporting our hypothesis that administration of a threshold concentration of SNS-595 sustained over a defined period of time results in disease remissions in patients with acute leukemias," said Daniel C. Adelman, M.D., Sunesis' Senior Vice President, Research and Development. "Based on these recent data from our Phase 1 trial, a potential relationship between dose, pharmacodynamic target modulation and clinical response appears to be emerging which should allow us to select doses rationally for our planned Phase 2 clinical studies. With clinical responses observed to date in a study population with relapsed and/or refractory acute leukemias, we expect that SNS-595 will continue to show positive evidence of clinically meaningful activity as we escalate dosing in both treatment schedules to the MTD in this trial."

Dose escalation is in subsequent cohorts is continuing, with a 72 mg/m2 weekly dose cohort and a 50 mg/m2 twice-weekly cohort currently enrolling. Once the maximum tolerated dose (MTD) has been identified in each schedule, the study will enroll up to 10 additional patients at the MTD for each dosing regimen. Sunesis currently anticipates completing the clinical trial in time to report final results at the American Society of Hematology (ASH) meeting in Atlanta in December of this year.

SNS-595 is a replication-dependent DNA damaging agent that causes double- stranded DNA breaks, irreversible G2 arrest, and rapid apoptosis. The ongoing Phase 1 trial is being conducted by leading investigators at the H. Lee Moffitt Cancer Center & Research Institute, Johns Hopkins Hospital and the University of Texas, MD Anderson Cancer Center. The Phase 1 study is designed to assess the safety, tolerability and pharmacokinetics of SNS-595 and to establish a recommended Phase 2 dose for further testing among patients with acute leukemia. In addition, evidence fr
'"/>